* HEMARINA *
2007 - Bretagne
Morlaix
www.hemarina.com Discovery, Drugs
Key words: Hemoglobin, Blood-transfers, Transfusion, Sea-Invertebrate, Arenicole
Mission: to develop a new generation of oxygen-carrier for therapeutical and industrial applications (to help cope with the huge deficit of blood worldwide), based on extraction and purification from a marine organism
Clients: Pharmaceutical industry (developement limited to early stage), Biotechs
info@hemarina.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Spin-off |
Managing Dir.-CEO: Zal (Franck) [co-founder, born 1966, Ph.D. oceanography, ex-CNRS]
Sc.Dir.-CSO: Zal (Franck)
Techn.Dir.-CTO: Rousselot (Morgane), [co-founder, Ph.D., Eng. ENSCMu, ex-GSK]
Fin.Dir.-CFO:
BusDev: Chasseriau (Jacques) [Ph.D.]
Financers (Hist.): privately-owned, Inserm Transfert Initiative, Synergie Finance, Vaneau, and various business angels (registered capital 2007 = 0.26 M€) | Turnover (M€) : 0.002 (2009)
Total funding (M€) : n.a.
Last funding (M€) : 3.0
Focus : Blood
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2010 .07 | 2nd round-financing : 3.0 M€, by Inserm Transfert Initiative, Finistère Angels, Angels Santé, Armor Angels, XMP Business Angels, Synergie Finance, Vaneau | RFINB | [3 years] |
| 2010 .03 | Partnering marketing agreement on HemoxCell distribution in France by Abcys | MKTG | [3 years] |
| 2007 .03 | Company founded by Franck Zal, Morgane Rousselot, Gilles Avenard [born 1951, M.D., ex-Hoechst-Marion-Roussel, CNTS, BioAlliance], as a spin-off of CNRS and Pierre-et-Marie-Curie University | ORGF | [0 year] | Actualisation / Updating: 21-Sep-2011 |
|
